SEATTLE, March 14, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that preclinical data for new bispecific antibody candidates targeting CD123 and CD3 will be presented in a poster session at the 2017 Annual Meeting of the American Association for Cancer Research (AACR) to be held in Washington D.C., April 1-5, 2017.
Based on Aptevo’s proprietary ADAPTIR™ protein therapeutic platform, the Company’s latest bispecific candidates targeting CD123 were designed to redirect T-cell cytotoxicity to CD123-expressing tumors cells, a cell surface receptor highly expressed in several hematological malignancies. Results being presented at AACR will examine the in vitro and in vivo activity of optimized lead candidates, APVO436 and APVO437, in preclinical models of acute myeloid leukemia (AML).
|Title:||Bispecific anti-CD123 x anti-CD3 ADAPTIR Molecules for Redirected T-cell Cytotoxicity in Hematological Malignancies|
|Date/Time:||April 2, 2017 – 1:00 – 5:00 pm ET|
|Session Title:||T-Cell Immunity to Cancer – New Progress (Immunology)|
Abstracts for the AACR annual meeting are available and can be viewed online at www.aacr.org. Aptevo’s poster presentation will be available on the Investor Relations section of the Company’s website at www.aptevotherapeutics.com following the poster session.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. Aptevo has four commercial products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.
Source: Aptevo Therapeutics Stacey Jurchison Senior Director, Investor Relations and Corporate Communications 206-859-6628 JurchisonS@apvo.com